Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

S.Africa says vaccines, prior infection help mildness of COVID cases

Published 12/17/2021, 04:36 AM
Updated 12/17/2021, 12:28 PM
© Reuters. FILE PHOTO: A pharmacist prepares a dose of the coronavirus disease (COVID-19) Pfizer vaccine amidst the spread of the SARS-CoV-2 variant Omicron in Johannesburg, South Africa, December 04, 2021. REUTERS/Sumaya Hisham
JNJ
-

By Alexander Winning

JOHANNESBURG (Reuters) -South Africa's health minister said on Friday that the government believed that vaccines and high levels of prior COVID-19 infection were helping to keep disease milder in a wave driven by the Omicron variant.

There have been early anecdotal accounts suggesting that Omicron is causing less severe illness than previous variants in South Africa but scientists say it is too early to draw firm conclusions.

The country reported a record number of daily infections earlier this week.

"We believe that it might not necessarily just be that Omicron is less virulent, but ... coverage of vaccination (and) ... natural immunity of people who have already had contact with the virus is also adding to the protection," Health Minister Joe Phaahla told a news conference. "That's why we are seeing mild illness."

South Africa has given 44% of its adult population at least one dose of COVID-19 vaccine, more than many African countries but well short of the government's year-end target. But among the over-50s vaccination coverage levels are over 60%.

Addressing the same news conference, Michelle Groome from the National Institute for Communicable Diseases (NICD) said there had been an uptick in COVID-19 hospital admissions and deaths.

"Starting to see a slight increase in deaths nationally, but once again this level is very much lower even than the baseline period we were seeing between the second and third waves," said Groome, who heads the NICD's division of public health, surveillance and response.

Waasila Jassat, a public health specialist at the NICD, estimated that of the COVID-19 related deaths that had happened in hospitals since mid-November more than half of the people who had died had co-morbidities, or tended to be old, and "a fair proportion of them were admitted for other reasons and died from other causes".

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

She said that vaccination data on those who had died were incomplete but it seemed from self-reported information that 93% of the deaths were among either unvaccinated or not fully vaccinated individuals. She added that a further 3.5% of those who had died had been vaccinated more than five or six months ago.

Phaahla said early indications were that infections might have peaked in the most populated Gauteng province, where cases initially surged.

He added that in the coming week the health department would report back to the National Coronavirus Command Council on whether COVID-19 restrictions should be adjusted.

President Cyril Ramaphosa, who tested positive for COVID-19 on Sunday, is making good progress with his recovery from COVID-19 while continuing to receive treatment for mild symptoms, the presidency said on Friday.

Ramaphosa was given Johnson & Johnson (NYSE:JNJ)'s one-dose vaccine in February.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.